Tags

Type your tag names separated by a space and hit enter

Detection of influenza A(H3N2) viruses exhibiting reduced susceptibility to the novel cap-dependent endonuclease inhibitor baloxavir in Japan, December 2018.
Euro Surveill. 2019 Jan; 24(3)ES

Abstract

The novel cap-dependent endonuclease inhibitor baloxavir marboxil was approved for the treatment of influenza virus infection in Japan in February 2018. Two influenza A(H3N2) viruses carrying an I38T substitution in the polymerase acidic subunit (PA) were detected in baloxavir-treated children in December 2018. This mutation is known to confer reduced susceptibility to baloxavir, and the two mutant viruses exhibited 76- and 120-fold reduced susceptibility to baloxavir.

Links

PMC Free PDF

Authors+Show Affiliations

Takashita E
Influenza Virus Research Center, National Institute of Infectious Diseases, Tokyo, Japan.
Kawakami C
Yokohama City Institute of Public Health, Kanagawa, Japan.
Morita H
Influenza Virus Research Center, National Institute of Infectious Diseases, Tokyo, Japan.
Ogawa R
Influenza Virus Research Center, National Institute of Infectious Diseases, Tokyo, Japan.
Fujisaki S
Influenza Virus Research Center, National Institute of Infectious Diseases, Tokyo, Japan.
Shirakura M
Influenza Virus Research Center, National Institute of Infectious Diseases, Tokyo, Japan.
Miura H
Influenza Virus Research Center, National Institute of Infectious Diseases, Tokyo, Japan.
Nakamura K
Influenza Virus Research Center, National Institute of Infectious Diseases, Tokyo, Japan.
Kishida N
Influenza Virus Research Center, National Institute of Infectious Diseases, Tokyo, Japan.
Kuwahara T
Influenza Virus Research Center, National Institute of Infectious Diseases, Tokyo, Japan.
Mitamura K
Eiju General Hospital, Tokyo, Japan.
Abe T
Abe Children's Clinic, Kanagawa, Japan.
Ichikawa M
Ichikawa Children's Clinic, Kanagawa, Japan.
Yamazaki M
Zama Children's Clinic, Kanagawa, Japan.
Watanabe S
Influenza Virus Research Center, National Institute of Infectious Diseases, Tokyo, Japan.
Odagiri T
Influenza Virus Research Center, National Institute of Infectious Diseases, Tokyo, Japan.
Influenza Virus Surveillance Group of Japan
The members of the group are listed at the end of the article.

MeSH

Amino Acid SubstitutionAntiviral AgentsDibenzothiepinsDrug Resistance, ViralEndonucleasesHumansInfluenza A Virus, H3N2 SubtypeInfluenza, HumanJapanMicrobial Sensitivity TestsMorpholinesOxazinesPyridinesPyridonesThiepinsTreatment OutcomeTriazines

Pub Type(s)

Journal Article

Language

eng

PubMed ID

30670142

Citation

Takashita, Emi, et al. "Detection of Influenza A(H3N2) Viruses Exhibiting Reduced Susceptibility to the Novel Cap-dependent Endonuclease Inhibitor Baloxavir in Japan, December 2018." Euro Surveillance : Bulletin Europeen Sur Les Maladies Transmissibles = European Communicable Disease Bulletin, vol. 24, no. 3, 2019.
Takashita E, Kawakami C, Morita H, et al. Detection of influenza A(H3N2) viruses exhibiting reduced susceptibility to the novel cap-dependent endonuclease inhibitor baloxavir in Japan, December 2018. Euro Surveill. 2019;24(3).
Takashita, E., Kawakami, C., Morita, H., Ogawa, R., Fujisaki, S., Shirakura, M., Miura, H., Nakamura, K., Kishida, N., Kuwahara, T., Mitamura, K., Abe, T., Ichikawa, M., Yamazaki, M., Watanabe, S., & Odagiri, T. (2019). Detection of influenza A(H3N2) viruses exhibiting reduced susceptibility to the novel cap-dependent endonuclease inhibitor baloxavir in Japan, December 2018. Euro Surveillance : Bulletin Europeen Sur Les Maladies Transmissibles = European Communicable Disease Bulletin, 24(3). https://doi.org/10.2807/1560-7917.ES.2019.24.3.1800698
Takashita E, et al. Detection of Influenza A(H3N2) Viruses Exhibiting Reduced Susceptibility to the Novel Cap-dependent Endonuclease Inhibitor Baloxavir in Japan, December 2018. Euro Surveill. 2019;24(3) PubMed PMID: 30670142.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Detection of influenza A(H3N2) viruses exhibiting reduced susceptibility to the novel cap-dependent endonuclease inhibitor baloxavir in Japan, December 2018. AU - Takashita,Emi, AU - Kawakami,Chiharu, AU - Morita,Hiroko, AU - Ogawa,Rie, AU - Fujisaki,Seiichiro, AU - Shirakura,Masayuki, AU - Miura,Hideka, AU - Nakamura,Kazuya, AU - Kishida,Noriko, AU - Kuwahara,Tomoko, AU - Mitamura,Keiko, AU - Abe,Takashi, AU - Ichikawa,Masataka, AU - Yamazaki,Masahiko, AU - Watanabe,Shinji, AU - Odagiri,Takato, AU - ,, PY - 2019/1/24/entrez PY - 2019/1/24/pubmed PY - 2020/7/10/medline KW - Influenza virus KW - baloxavir acid KW - baloxavir marboxil KW - cap-dependent endonuclease inhibitor KW - resistant JF - Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin JO - Euro Surveill VL - 24 IS - 3 N2 - The novel cap-dependent endonuclease inhibitor baloxavir marboxil was approved for the treatment of influenza virus infection in Japan in February 2018. Two influenza A(H3N2) viruses carrying an I38T substitution in the polymerase acidic subunit (PA) were detected in baloxavir-treated children in December 2018. This mutation is known to confer reduced susceptibility to baloxavir, and the two mutant viruses exhibited 76- and 120-fold reduced susceptibility to baloxavir. SN - 1560-7917 UR - https://www.unboundmedicine.com/medline/citation/30670142/Detection_of_influenza_A_H3N2__viruses_exhibiting_reduced_susceptibility_to_the_novel_cap_dependent_endonuclease_inhibitor_baloxavir_in_Japan_December_2018_ DB - PRIME DP - Unbound Medicine ER -
Grapherence [↓34 ↑6]

Related Citations

More